Innate Pharma SA, a clinical-stage biotechnology company, has announced its participation in the upcoming Stifel Healthcare Conference and the Jefferies Global Healthcare Conference. This engagement is crucial as it reflects the company's ongoing efforts to connect with investors and stakeholders in the biotechnology sector.
The Stifel Healthcare Conference is scheduled for November 10-12, 2026, in New York, while the Jefferies Global Healthcare Conference will take place from November 16-19, 2026, in London. Innate Pharma's executive team will be present at both events, aiming to showcase its innovative immunotherapy solutions for cancer patients.
According to the filing dated October 21, 2026, Innate Pharma stated, "Members of its executive team will participate in the following investor conferences." This highlights the company's proactive approach in engaging with the investment community.
Innate Pharma operates within the biological products industry, specifically focusing on developing immunotherapies for cancer patients. The company's participation in these conferences may impact various stakeholders, including investors, potential partners, and competitors in the biotechnology field.
Looking ahead, Innate Pharma's involvement in these conferences could lead to further announcements or collaborations, although the filing does not specify what happens next.
Event Details and Participation
At the Stifel Healthcare Conference, Innate Pharma will participate in a fireside chat scheduled for November 10, 2026, at 2:00 p.m. ET / 8:00 p.m. CET. This interactive session will allow attendees to engage with the company's executive team, providing insights into their strategies and developments in immunotherapy.
For the Jefferies Global Healthcare Conference, the company will be present from November 16-19, 2026, in London, further expanding its outreach to international investors and stakeholders.
Company Overview
Innate Pharma is focused on developing innovative and differentiated next-generation antibody therapeutics, with a proprietary pipeline that includes antibody-drug conjugates (ADCs). Among its leading candidates is IPH4502, which is currently in clinical development for solid tumors. Additionally, the company is advancing two partnered late-stage assets: lacutamab for T-cell lymphomas and monalizumab for non-small cell lung cancer (NSCLC).
The company has established collaborations with notable biopharmaceutical firms such as Sobi and AstraZeneca, enhancing its capabilities in immuno-oncology and expanding its research and development efforts.
Contact Information
For further inquiries, interested parties can contact Stéphanie Cornen, VP of Investor Relations & Corporate Communications, via email at stephanie.cornen@innate-pharma.fr. General investor relations can be reached at investors@innate-pharma.fr.